JP2009513657A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009513657A5 JP2009513657A5 JP2008537930A JP2008537930A JP2009513657A5 JP 2009513657 A5 JP2009513657 A5 JP 2009513657A5 JP 2008537930 A JP2008537930 A JP 2008537930A JP 2008537930 A JP2008537930 A JP 2008537930A JP 2009513657 A5 JP2009513657 A5 JP 2009513657A5
- Authority
- JP
- Japan
- Prior art keywords
- matrix
- agent
- rate regulating
- weight
- glyceryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011159 matrix material Substances 0.000 claims 37
- 230000001105 regulatory effect Effects 0.000 claims 11
- 230000004888 barrier function Effects 0.000 claims 10
- 239000003981 vehicle Substances 0.000 claims 6
- 239000002775 capsule Substances 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 239000000463 material Substances 0.000 claims 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 230000000069 prophylactic effect Effects 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 4
- 229940039227 diagnostic agent Drugs 0.000 claims 3
- 239000000032 diagnostic agent Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000004094 surface-active agent Substances 0.000 claims 3
- 239000001961 anticonvulsive agent Substances 0.000 claims 2
- 229940125714 antidiarrheal agent Drugs 0.000 claims 2
- 239000003793 antidiarrheal agent Substances 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000013270 controlled release Methods 0.000 claims 2
- 230000001276 controlling effect Effects 0.000 claims 2
- 230000009977 dual effect Effects 0.000 claims 2
- 239000007903 gelatin capsule Substances 0.000 claims 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000003921 oil Substances 0.000 claims 2
- 235000019198 oils Nutrition 0.000 claims 2
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 229940125725 tranquilizer Drugs 0.000 claims 2
- 239000003204 tranquilizing agent Substances 0.000 claims 2
- 230000002936 tranquilizing effect Effects 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 1
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 claims 1
- GHHURQMJLARIDK-UHFFFAOYSA-N 2-hydroxypropyl octanoate Chemical compound CCCCCCCC(=O)OCC(C)O GHHURQMJLARIDK-UHFFFAOYSA-N 0.000 claims 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- LKUNXBRZDFMZOK-GFCCVEGCSA-N Capric acid monoglyceride Natural products CCCCCCCCCC(=O)OC[C@H](O)CO LKUNXBRZDFMZOK-GFCCVEGCSA-N 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 claims 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 230000003444 anaesthetic effect Effects 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000004004 anti-anginal agent Substances 0.000 claims 1
- 230000001088 anti-asthma Effects 0.000 claims 1
- 230000001773 anti-convulsant effect Effects 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 229940124345 antianginal agent Drugs 0.000 claims 1
- 239000003416 antiarrhythmic agent Substances 0.000 claims 1
- 239000000924 antiasthmatic agent Substances 0.000 claims 1
- 229940125681 anticonvulsant agent Drugs 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 229940125684 antimigraine agent Drugs 0.000 claims 1
- 239000002282 antimigraine agent Substances 0.000 claims 1
- 239000003096 antiparasitic agent Substances 0.000 claims 1
- 229940125687 antiparasitic agent Drugs 0.000 claims 1
- 239000000939 antiparkinson agent Substances 0.000 claims 1
- 239000002221 antipyretic Substances 0.000 claims 1
- 229940125716 antipyretic agent Drugs 0.000 claims 1
- 229940121383 antituberculosis agent Drugs 0.000 claims 1
- 239000003699 antiulcer agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical group CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims 1
- 235000013871 bee wax Nutrition 0.000 claims 1
- 239000012166 beeswax Substances 0.000 claims 1
- 229940125388 beta agonist Drugs 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 230000002051 biphasic effect Effects 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 239000002327 cardiovascular agent Substances 0.000 claims 1
- 229940125692 cardiovascular agent Drugs 0.000 claims 1
- 239000000679 carrageenan Substances 0.000 claims 1
- 235000010418 carrageenan Nutrition 0.000 claims 1
- 229920001525 carrageenan Polymers 0.000 claims 1
- 229940113118 carrageenan Drugs 0.000 claims 1
- 239000004359 castor oil Substances 0.000 claims 1
- 235000019438 castor oil Nutrition 0.000 claims 1
- 229920003086 cellulose ether Polymers 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 239000004205 dimethyl polysiloxane Substances 0.000 claims 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 238000005538 encapsulation Methods 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 125000005456 glyceride group Chemical group 0.000 claims 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 1
- 229940049654 glyceryl behenate Drugs 0.000 claims 1
- 229940087068 glyceryl caprylate Drugs 0.000 claims 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 claims 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 claims 1
- 229940075529 glyceryl stearate Drugs 0.000 claims 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 239000003326 hypnotic agent Substances 0.000 claims 1
- 230000000147 hypnotic effect Effects 0.000 claims 1
- 229940126904 hypoglycaemic agent Drugs 0.000 claims 1
- 229960003943 hypromellose Drugs 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 229940057917 medium chain triglycerides Drugs 0.000 claims 1
- 239000002480 mineral oil Substances 0.000 claims 1
- 235000010446 mineral oil Nutrition 0.000 claims 1
- 229940042472 mineral oil Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229940035363 muscle relaxants Drugs 0.000 claims 1
- 239000003158 myorelaxant agent Substances 0.000 claims 1
- 239000004081 narcotic agent Substances 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- 229940049964 oleate Drugs 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- 150000002888 oleic acid derivatives Polymers 0.000 claims 1
- 150000002889 oleic acids Polymers 0.000 claims 1
- 230000001734 parasympathetic effect Effects 0.000 claims 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims 1
- 239000008389 polyethoxylated castor oil Substances 0.000 claims 1
- 229950008882 polysorbate Drugs 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 229940026235 propylene glycol monolaurate Drugs 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 239000003368 psychostimulant agent Substances 0.000 claims 1
- LKUNXBRZDFMZOK-UHFFFAOYSA-N rac-1-monodecanoylglycerol Chemical compound CCCCCCCCCC(=O)OCC(O)CO LKUNXBRZDFMZOK-UHFFFAOYSA-N 0.000 claims 1
- 230000000580 secretagogue effect Effects 0.000 claims 1
- 239000000932 sedative agent Substances 0.000 claims 1
- 230000001624 sedative effect Effects 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 239000007901 soft capsule Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 239000000021 stimulant Substances 0.000 claims 1
- 230000002889 sympathetic effect Effects 0.000 claims 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 claims 1
- 239000000814 tuberculostatic agent Substances 0.000 claims 1
- 229940124549 vasodilator Drugs 0.000 claims 1
- 239000003071 vasodilator agent Substances 0.000 claims 1
- 235000015112 vegetable and seed oil Nutrition 0.000 claims 1
- 239000008158 vegetable oil Substances 0.000 claims 1
- 239000000230 xanthan gum Substances 0.000 claims 1
- 235000010493 xanthan gum Nutrition 0.000 claims 1
- 229920001285 xanthan gum Polymers 0.000 claims 1
- 229940082509 xanthan gum Drugs 0.000 claims 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73051405P | 2005-10-26 | 2005-10-26 | |
| US60/730,514 | 2005-10-26 | ||
| PCT/US2006/041722 WO2007050724A2 (en) | 2005-10-26 | 2006-10-26 | Lipophilic vehicle-based dual controlled release matrix system as capsule fill |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013133882A Division JP2013216681A (ja) | 2005-10-26 | 2013-06-26 | カプセル充墳物としての親油性ベヒクルに基づく二重制御された放出マトリクスシステム |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009513657A JP2009513657A (ja) | 2009-04-02 |
| JP2009513657A5 true JP2009513657A5 (https=) | 2009-12-17 |
| JP5406529B2 JP5406529B2 (ja) | 2014-02-05 |
Family
ID=37968540
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008537930A Expired - Fee Related JP5406529B2 (ja) | 2005-10-26 | 2006-10-26 | カプセル充墳物としての親油性ベヒクルに基づく二重制御された放出マトリクスシステム |
| JP2013133882A Pending JP2013216681A (ja) | 2005-10-26 | 2013-06-26 | カプセル充墳物としての親油性ベヒクルに基づく二重制御された放出マトリクスシステム |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013133882A Pending JP2013216681A (ja) | 2005-10-26 | 2013-06-26 | カプセル充墳物としての親油性ベヒクルに基づく二重制御された放出マトリクスシステム |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8293270B2 (https=) |
| EP (1) | EP1951208A2 (https=) |
| JP (2) | JP5406529B2 (https=) |
| CN (1) | CN101351196B (https=) |
| CA (1) | CA2627351C (https=) |
| WO (1) | WO2007050724A2 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2593047T3 (es) | 2006-02-03 | 2016-12-05 | Opko Renal, Llc | Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3 |
| ES2670029T3 (es) | 2006-06-21 | 2018-05-29 | Opko Ireland Global Holdings, Ltd. | Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D |
| US11752158B2 (en) | 2007-04-25 | 2023-09-12 | Eirgen Pharma Ltd. | Method of treating vitamin D insufficiency and deficiency |
| KR20190028822A (ko) | 2007-04-25 | 2019-03-19 | 사이토크로마 인코포레이티드 | 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물 |
| HUE073014T2 (hu) | 2007-04-25 | 2025-12-28 | Opko Renal Llc | Eljárás a másodlagos hyperparathyreoidismus biztonságos és hatékony kezelésére és megelõzésére krónikus vesebetegség esetén |
| CA2689434C (en) * | 2007-06-04 | 2017-09-26 | Shear/Kershman Laboratories, Inc. | Tamper resistant lipid-based oral dosage form for opioid agonists |
| US8177950B2 (en) * | 2007-11-21 | 2012-05-15 | Tennessee Technological University | Thermoresponsive microparticle composite hydrogels for electrophoresis |
| EP2281058B1 (en) | 2008-04-02 | 2016-06-29 | Opko Ireland Global Holdings, Ltd. | Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders |
| CA2739882A1 (en) * | 2008-10-22 | 2010-04-29 | Santen Pharmaceutical Co., Ltd. | Pharmaceutical composition improving intestinal absorption |
| WO2011123476A1 (en) | 2010-03-29 | 2011-10-06 | Cytochroma Inc. | Methods and compositions for reducing parathyroid levels |
| EP2782603A1 (en) | 2011-11-25 | 2014-10-01 | Danmarks Tekniske Universitet | Formulation of solid nano-sized particles in a gel-forming system |
| US20150250751A1 (en) * | 2012-10-16 | 2015-09-10 | Wockhardt Limited | Pharmaceutical compositions of diclofenac or salts thereof |
| WO2014060857A1 (en) * | 2012-10-19 | 2014-04-24 | Wockhardt Limited | Pharmaceutical compositions of diclofenac or salts thereof |
| US10420729B2 (en) | 2013-03-15 | 2019-09-24 | R.P. Scherer Technologies, Llc | Abuse resistant capsule |
| KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 ｄ 방출 제형 |
| US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
| ES2713157T3 (es) | 2014-02-28 | 2019-05-20 | Banner Life Sciences Llc | Cápsulas blandas entéricas de liberación controlada de ésteres de fumarato |
| US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
| US10182992B2 (en) | 2014-04-07 | 2019-01-22 | Patheon Softgels Inc. | Abuse-deterrent controlled release formulations |
| US10772842B2 (en) | 2015-01-09 | 2020-09-15 | Patheon Softgels Inc. | Abuse-deterrent opioids |
| US10220047B2 (en) | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| JP7032322B2 (ja) | 2016-03-28 | 2022-03-08 | オプコ アイルランド グローバル ホールディングス リミテッド | ビタミンｄ治療法 |
| WO2017189621A1 (en) * | 2016-04-26 | 2017-11-02 | Symbiotic Health Inc. | Stable macroemulsion for oral delivery of solubilized peptides, protein, and cellular therapeutics |
| EA202092092A1 (ru) * | 2018-03-15 | 2021-02-15 | Сересин Инк. | Фармацевтические композиции с высокими лекарственными нагрузками среднецепочечных триглицеридов и связанные с ними способы |
| WO2020053665A2 (en) * | 2018-09-13 | 2020-03-19 | Ftf Pharma Private Limited | Non-aqueous chemotherapeutic suspensions for oral dosage |
| EP3863603A1 (en) * | 2018-10-08 | 2021-08-18 | Chanelle Pharmaceuticals Manufacturing Ltd. | A soft-gel capsule formulation, method of manufacture and use thereof |
| US11903918B2 (en) | 2020-01-10 | 2024-02-20 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2016A (en) * | 1841-03-26 | Mode of constructing fireplaces and chimney-staoks ii | ||
| US4424235A (en) * | 1981-09-14 | 1984-01-03 | Hoffmann-La Roche Inc. | Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor |
| CA2017916C (en) * | 1989-06-07 | 1999-02-02 | Minoru Aoki | Etoposide preparations |
| US5498422A (en) * | 1991-04-08 | 1996-03-12 | Nippon Shinyaku Company Limited | Sustained release capsule |
| US5662933A (en) * | 1993-09-09 | 1997-09-02 | Edward Mendell Co., Inc. | Controlled release formulation (albuterol) |
| WO1995011668A1 (en) * | 1993-10-29 | 1995-05-04 | Reckitt & Colman Products Limited | Gelatin capsule fill able to foam |
| GB9322314D0 (en) * | 1993-10-29 | 1993-12-15 | Scherer Ltd R P | Foam generating capsules |
| US5447729A (en) * | 1994-04-07 | 1995-09-05 | Pharmavene, Inc. | Multilamellar drug delivery systems |
| FR2739558B1 (fr) * | 1995-10-05 | 1997-11-28 | Innothera Lab Sa | Forme galenique unitaire pour hormonotherapie locale de la secheresse vaginale |
| FR2748209B1 (fr) | 1996-05-06 | 1998-06-05 | Adir | Composition pharmaceutique a base de matrices lipophiles stabilisees pour la liberation controlee de principes actifs |
| US6027746A (en) * | 1997-04-23 | 2000-02-22 | Warner-Lambert Company | Chewable soft gelatin-encapsulated pharmaceutical adsorbates |
| IT1291362B1 (it) * | 1997-05-13 | 1999-01-07 | Vectorpharma Int | Composizioni farmaceutiche multicomponente bifasiche contenenti sostanze atte a modificare la partizione dei principi attivi |
| JP4139909B2 (ja) * | 1997-06-12 | 2008-08-27 | キャタレント・ジャパン株式会社 | ソフトカプセル用基剤 |
| GB2328443B (en) * | 1997-08-21 | 2001-09-05 | Reckitt & Colmann Prod Ltd | In situ formation of pharmaceutically acceptable polymeric material |
| BE1011363A3 (fr) * | 1997-09-11 | 1999-08-03 | Smb Technology | Capsules semi-solides autoemulsionnables matricielles a action prolongee. |
| US6056977A (en) * | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
| GB2331458B (en) | 1997-11-21 | 2002-07-31 | Gursharan Singh Moonga | Solubilising systems for difficult pharmaceutical actives for preparing concentrated stable solutions for encapsulation into soft gelatine |
| ATE429210T1 (de) | 1998-01-20 | 2009-05-15 | Applied Analytical Ind Inc | Orale flüssige zusammensetzungen |
| FR2782006B1 (fr) * | 1998-08-07 | 2002-04-19 | Gattefosse Ets Sa | Composition a liberation prolongee apte a former une micro-emulsion |
| US6251426B1 (en) * | 1999-09-02 | 2001-06-26 | Banner Pharmacaps, Inc. | Ibuprofen-containing softgels |
| EA200200415A1 (ru) | 1999-09-27 | 2002-10-31 | Американ Цианамид Компани | Композиция фармацевтического носителя |
| EP1175205B1 (en) | 1999-11-12 | 2006-06-14 | Abbott Laboratories | Solid dispersion comprising ritonavir, fenofibrate or griseofulvin |
| DE60040729D1 (de) * | 1999-12-20 | 2008-12-18 | Shiseido Co Ltd | Zubereitungen zur äusseren anwendung auf der haut enthaltend diethoxyethylsuccinat |
| US6491950B1 (en) * | 2000-08-07 | 2002-12-10 | Kos Pharmaceuticals, Inc. | Controlled release pharmaceutical composition |
| US6524615B2 (en) * | 2001-02-21 | 2003-02-25 | Kos Pharmaceuticals, Incorporated | Controlled release pharmaceutical composition |
| US20030105141A1 (en) | 2001-04-17 | 2003-06-05 | Ping Gao | Finely self-emulsifiable pharmaceutical composition |
| WO2003061626A1 (en) * | 2002-01-18 | 2003-07-31 | Control Delivery Systems, Inc. | Polymeric gel system for the controlled delivery of codrugs |
| IL164163A0 (en) | 2002-04-09 | 2005-12-18 | Pharmacia Corp | Process for preparing a finely self-emulsifiable pharmaceutical composition |
| FR2838349B1 (fr) * | 2002-04-15 | 2004-06-25 | Laurence Paris | Compositions liquides pour capsules molle a liberation prolongee et leur procede de fabrication |
| US20050255152A1 (en) * | 2002-04-18 | 2005-11-17 | President And Fellows Of Harvard College | System for enhanced targeted delivery |
| US20040033257A1 (en) * | 2002-05-30 | 2004-02-19 | Strides Inc. | Pharmaceutical formulation in a drug delivery system and process for preparing the same |
| US7399488B2 (en) * | 2002-07-05 | 2008-07-15 | Collegium Pharmaceutical, Inc. | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
| DK1545475T3 (da) | 2002-10-01 | 2014-07-28 | Banner Pharmacaps Inc | Enterisk sammensætning til fremstillingen af blød kapselvæg |
| SI2279729T1 (sl) * | 2003-07-17 | 2016-10-28 | Banner Life Sciences, LLC | Pripravki z nadziranim sproščanjem |
| US20050096365A1 (en) * | 2003-11-03 | 2005-05-05 | David Fikstad | Pharmaceutical compositions with synchronized solubilizer release |
| AU2005206084A1 (en) * | 2004-01-09 | 2005-08-04 | Wyeth | Microemulsions for pharmaceutical compositions |
| US20060286172A1 (en) * | 2005-06-03 | 2006-12-21 | Anu Mahashabde | Pharmaceutical compositions comprising prostanoid-receptor agonists and methods of making and using the same |
-
2006
- 2006-10-26 CN CN200680045615XA patent/CN101351196B/zh not_active Expired - Fee Related
- 2006-10-26 JP JP2008537930A patent/JP5406529B2/ja not_active Expired - Fee Related
- 2006-10-26 WO PCT/US2006/041722 patent/WO2007050724A2/en not_active Ceased
- 2006-10-26 EP EP06826700A patent/EP1951208A2/en not_active Withdrawn
- 2006-10-26 CA CA2627351A patent/CA2627351C/en not_active Expired - Fee Related
- 2006-10-26 US US11/553,349 patent/US8293270B2/en not_active Expired - Fee Related
-
2013
- 2013-06-26 JP JP2013133882A patent/JP2013216681A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009513657A5 (https=) | ||
| CA2627351A1 (en) | Lipophilic vehicle-based dual controlled release matrix system | |
| CN112739328B (zh) | 大麻素的速释配方 | |
| AU668386B2 (en) | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms | |
| JP5903092B2 (ja) | 抗乱用ゲル状医薬組成物 | |
| US6524615B2 (en) | Controlled release pharmaceutical composition | |
| JP7323451B2 (ja) | フロルグルシノールおよびトリメチルフロログルシノールの医薬製剤 | |
| KR102851614B1 (ko) | 장애 치료를 위한 중수소화된 돔페리돈 조성물 및 방법 | |
| EP2906202A1 (en) | Oral drug delivery formulations | |
| JP2009514890A (ja) | テトラヒドロカンナビノールの改良された送達 | |
| CA2726793A1 (en) | Pulsatile release of valsartan | |
| JP2018520114A (ja) | イソトレチノインの１日１回経口医薬組成物 | |
| KR20010032320A (ko) | 용해된 파록세틴을 포함하는 제형 | |
| CN101874817B (zh) | 鸦胆子油肠溶微囊及其制备方法 | |
| KR20240125702A (ko) | 중수소화 돔페리돈 조성물, 방법, 및 제조 | |
| RU2018118603A (ru) | Фармацевтические композиции диметилфумарата | |
| CA3013123C (en) | Deuterated domperidone compositions and methods for therapy of disorders | |
| EA046180B1 (ru) | Фармацевтический состав флороглюцинола и триметилфлороглюцинола | |
| HK40029064A (en) | Deuterated domperidone compounds for use in ameliorating gastroesophageal reflux disease | |
| CN103156846A (zh) | 泮托拉唑钠肠溶片组合物及其制备方法 |